(Q44938727)

7 December 2017

title

HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity (English)

1 reference

7 December 2017

main subject

hepatocellular carcinoma

1 reference

Gang Ding

1

1 reference

7 December 2017

He-Dai Liu

2

1 reference

7 December 2017

Qian Huang

3

1 reference

7 December 2017

Hong-Xiang Liang

4

1 reference

7 December 2017

Zhao-Han Ding

5

1 reference

7 December 2017

Zhi-Jun Liao

6

1 reference

7 December 2017

Gang Huang

7

1 reference

7 December 2017

language of work or name

English

0 references

publication date

10 February 2013

1 reference

7 December 2017

1 reference

7 December 2017

volume

587

1 reference

7 December 2017

issue

7

1 reference

7 December 2017

page(s)

880-886

1 reference

Molecular targeted therapies in hepatocellular carcinoma

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Natural history of hepatitis-related hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Regulation and function of the p53 tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

DNA damage activates p53 through a phosphorylation-acetylation cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

The p53-Mdm2 module and the ubiquitin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

The role of HDAC6 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Histone deacetylase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Epigenetic-based therapies in cancer: progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

MDM2 expression during mouse embryogenesis and the requirement of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Yin Yang 1 is a negative regulator of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Abnormal structure and expression of p53 gene in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Transcription-independent pro-apoptotic functions of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.02.001

10.1016/J.FEBSLET.2013.02.001

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference